HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Steve Weitman Selected Research

Neoplasms (Cancer)

1/2014An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011.
9/2013The Development of a Minority Recruitment Plan for Cancer Clinical Trials.
4/2011Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
10/2006Discovery and development of clofarabine: a nucleoside analogue for treating cancer.
9/2006Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
11/2005Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
11/2005A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
5/2004Antitumor activity of a kinesin inhibitor.
7/2003Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study.
6/2002The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Steve Weitman Research Topics

Disease

11Neoplasms (Cancer)
01/2014 - 04/2002
3Neutropenia
09/2006 - 07/2003
2Leukemia
03/2005 - 11/2004
1Brain Neoplasms (Brain Tumor)
05/2018
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
04/2011
1Hematologic Neoplasms (Hematological Malignancy)
04/2011
1Fever (Fevers)
09/2006
1Ileus
11/2005
1Alopecia (Baldness)
11/2005
1Edema (Dropsy)
11/2005
1Fatigue
11/2005
1Melanoma (Melanoma, Malignant)
11/2005
1Nausea
11/2005
1Peripheral Nervous System Diseases (PNS Diseases)
11/2005
1Juvenile Myelomonocytic Leukemia
03/2005
1Body Weight (Weight, Body)
11/2004

Drug/Important Bio-Agent (IBA)

4NucleosidesIBA
04/2011 - 04/2002
4Clofarabine (Clolar)FDA Link
04/2011 - 11/2004
3tasidotinIBA
09/2006 - 11/2005
2Paclitaxel (Taxol)FDA LinkGeneric
05/2004 - 07/2003
1PolymersIBA
05/2018
1Atovaquone (Mepron)FDA Link
05/2018
1Alanine Transaminase (SGPT)IBA
11/2005
1Transaminases (Aminotransferases)IBA
11/2005
1Aspartic Acid (Aspartate)FDA Link
11/2005
1tipifarnib (R115777)IBA
03/2005
1Farnesyltranstransferase (Farnesyltransferase)IBA
03/2005
1triphosphoric acid (triphosphate)IBA
11/2004
1Proteins (Proteins, Gene)FDA Link
05/2004
1Antimitotic AgentsIBA
05/2004
1CK0106023IBA
05/2004
1KinesinsIBA
05/2004
1PorphyrinsIBA
06/2002
1Telomerase (Telomerase Reverse Transcriptase)IBA
06/2002
1tetra(4-N-methylpyridyl)porphineIBA
06/2002
1DNA (Deoxyribonucleic Acid)IBA
04/2002
1GemcitabineFDA Link
04/2002
1Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
04/2002
1DNA Ligase ATPIBA
04/2002
1gemcitabine triphosphateIBA
04/2002
1CytidineIBA
04/2002

Therapy/Procedure

3Therapeutics
01/2014 - 05/2004